# Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population

> **NCT02601976** · PHASE4 · COMPLETED · sponsor: **Getz Pharma** · enrollment: 64 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Peginterferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02601976
- **Lead sponsor:** Getz Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2012-09
- **Final completion:** 2014-09
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2018-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02601976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02601976, "Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02601976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*